Superworth

Vyome revenue HIND

Sales by quarter and over the last twelve months, from 2015.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
$27K
−46% on a year earlier
Fiscal year 2024
$5.8M
−33% on the year before

Vyome's twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was $27K, down 46% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024$5.8M−33%
FY2023$8.7M−23%
FY2022$11.2M−17%
FY2021$13.6M+315%
FY2019$3.3M−64%
FY2018$9.1M−8%
FY2017$9.9M+192%
FY2016$3.4M−16%
FY2015$4Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$27K−46%n/a
Q1 FY26$31.6K−84%n/a
Q3 FY25$34.6K−59%$2.1M
Q2 FY25$50K−97%$2.1M
Q1 FY25$198.6K−90%$4.1M
Q4 FY24$1.8M−9%$5.8M
Q3 FY24$84.5K−96%$6M
Q2 FY24$2M−13%$8M
Q1 FY24$1.9M−15%$8.3M
Q4 FY23$2M−36%$8.7M
Q3 FY23$2.2M−23%$9.8M
Q2 FY23$2.3M−22%$10.4M

Against its peers

Companies in Drug Manufacturers - General nearest Vyome's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
HINDVyomen/m
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
Peer median$114.8M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Vyome

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.